anti cancer medicine

Sutinat 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibition for Targeted Oncology. Sutinat 12.5 mg Capsule is a high-potency oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutinat is a cornerstone in modern precision medicine. Manufactured by Natco Pharma Ltd., a global leader in high-quality oncology generics, it is engineered to disrupt the life cycle of cancer cells by blocking specific signaling pathways that promote tumor growth and vascularization. Therapeutic Indications and Clinical Usage Sutinat 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often serving as a primary first-line therapy to improve progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy) in high-risk patients. Mechanism of Action: How Sutinat 12.5mg Works Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutinat helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutinat 12.5 mg is an oral medication. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5mg or as adjusted) without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state levels. Safety Profile and Clinical Monitoring Treatment with Sutinat 12.5 mg requires vigilant medical oversight for: Cardiovascular Health: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or hair depigmentation during the treatment cycle. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Svitinib 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Oncology. Svitinib 50mg Capsule is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, the 50 mg dosage is the standard therapeutic strength used to achieve profound tumor suppression in aggressive cancers. Manufactured by Sun Pharma, Svitinib is engineered to disrupt the signaling pathways that allow cancer cells to grow, divide, and develop the blood supply necessary for tumor survival. Therapeutic Indications and Clinical Usage Svitinib 50mg is a cornerstone in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: Used in high-risk patients to prevent the recurrence of RCC following a nephrectomy. Mechanism of Action: How Svitinib 50mg Works Svitinib 50mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This “starves“ the tumor by preventing the formation of new blood vessels. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled proliferation of malignant cells. Metastasis Inhibition: By disrupting these vital biological pathways, Svitinib helps limit the cancer's ability to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Method of Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Adjustments: Based on individual patient tolerability, oncologists may adjust the dose to 37.5 mg or 25 mg using lower-strength capsules. Safety Profile and Professional Monitoring High-strength TKI therapy requires vigilant medical supervision to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are mandatory, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin discoloration (yellowing), hair depigmentation, or hand-foot syndrome. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is standard practice. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container to protect them from moisture and light. Safety: Caregivers should handle the medication with care, avoid contact with broken capsules, and keep it out of reach of children. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutekast 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Malignancies. Sutekast 50 mg Capsule is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, the 50 mg dosage is the standard therapeutic strength used to achieve profound tumor suppression in aggressive cancers. Manufactured by Aprazer Healthcare, Sutekast is engineered to disrupt the signaling pathways that allow cancer cells to grow, divide, and develop the blood supply necessary for tumor survival. Therapeutic Indications and Clinical Usage Sutekast 50 mg is a cornerstone in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: Used in high-risk patients to prevent the recurrence of RCC following a nephrectomy. Mechanism of Action: How Sutekast 50mg Works Sutekast 50 mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This “starves“ the tumor by preventing the formation of new blood vessels. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled proliferation of malignant cells. Metastasis Inhibition: By disrupting these vital biological pathways, Sutekast helps limit the cancer's ability to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Continuous Regimen (pNET): For pancreatic neuroendocrine tumors, a lower continuous daily dose (often 37.5 mg) may be derived from titration, though the 50 mg strength remains the baseline for many induction phases. Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring High-strength TKI therapy requires vigilant medical supervision to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are mandatory, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin discoloration (yellowing), hair depigmentation, or hand-foot syndrome. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is standard practice. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container to protect them from moisture and light. Safety: Caregivers should handle the medication with care, avoid contact with broken capsules, and keep out of reach of children. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Nitnib 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology Care Nitnib 12.5 mg Capsule is a high-efficacy, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Nitnib is a cornerstone in modern precision oncology. Manufactured by Sun Pharma, a global leader in high-quality pharmaceuticals, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 12.5 mg strength allows for precise dose titration, ensuring that patients receive the optimal therapeutic benefit while managing systemic tolerability. Therapeutic Indications and Global Clinical Usage Nitnib 12.5 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy. Mechanism of Action: How Nitnib 12.5mg Works Nitnib employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Nitnib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Nitnib 12.5 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Rcnet 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Inhibition for Precision Oncology. Rcnet 12.5mg Capsule is a high-potency oral therapeutic agent featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Rcnet is a cornerstone in modern targeted cancer therapy. Manufactured by RPG Life Sciences, it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Rcnet 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often serving as a primary first-line therapy. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific high-risk clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy). Mechanism of Action: How Rcnet 12.5mg Works Rcnet works through a dual-mechanism approach to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it effectively “starves“ the tumor by preventing the development of the new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Rcnet helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Rcnet 12.5mg is an oral medication. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration (e.g., reaching 25 mg, 37.5 mg, or 50 mg) based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Safety Profile and Clinical Monitoring Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or hair depigmentation during the treatment cycle. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sugistran 12.5 mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology. Sugistran 12.5 mg Capsule is a high-potency, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sugistran is a cornerstone in modern precision oncology. Manufactured by Zuventus Healthcare, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 12.5 mg strength allows for precise dose titration, ensuring that patients receive the optimal therapeutic benefit while managing systemic tolerability. Therapeutic Indications and Global Clinical Usage Sugistran 12.5 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sugistran 12.5mg Works Sugistran employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sugistran helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sugistran 12.5 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutekast 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Inhibition for Advanced Oncology Sutekast 12.5 mg Capsule is a potent, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. It is a specialized multi-targeted receptor tyrosine kinase (RTK) inhibitor designed to disrupt the life cycle of cancer cells. Manufactured by Aprazer Healthcare, Sutekast 12.5 mg is a vital therapeutic intervention in modern precision medicine, specifically engineered to inhibit tumor growth and prevent the formation of blood vessels that nourish malignant cells. Therapeutic Indications and Clinical Usage Sutekast 12.5 mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated as a primary treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Treatment: Utilized in certain high-risk scenarios to prevent cancer recurrence following a nephrectomy. Mechanism of Action: How Sutekast 12.5mg Works Sutekast works through a dual-action approach—inhibiting both tumor cell signaling and the tumor's blood supply: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutekast helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutekast 12.5 mg is an oral medication. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with Sutekast 12.5mg requires consistent medical oversight to manage potential side effects: Cardiovascular Health: Regular blood pressure monitoring is essential, as Sunitinib can cause hypertension. Hematological Checks: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Organ Function: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lynide 5mg Capsule (Lenalidomide): Precision Immunomodulatory Therapy for Oncology Care Lynide 5mg Capsule is a high-efficacy oral antineoplastic and immunomodulatory medication containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Glenmark Pharmaceuticals, a globally recognized leader in high-quality medicine, Lynide belongs to the class of drugs known as Immunomodulatory Imide Drugs (IMiDs). The 5mg strength is a vital dosage form used extensively for maintenance therapy, precise dose titration, and the management of chronic hematological malignancies. Therapeutic Indications and Clinical Usage Lynide 5mg is integrated into international oncology protocols for the management of several complex conditions: Multiple Myeloma (MM) Maintenance: Used as a long-term strategy following an autologous stem cell transplant (ASCT) to prolong progression-free survival and prevent disease relapse. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Administered in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lynide 5mg Works Lynide exerts a multi-pathway biological effect to combat malignant cells while enhancing the body's natural defenses: Cereblon Binding: It binds to the protein Cereblon, part of the E3 ubiquitin ligase complex. This leads to the targeted degradation of essential transcription factors that malignant cells rely on for survival. Immune System Activation: It stimulates the proliferation and activity of T-cells and Natural Killer (NK) cells, significantly increasing the body's innate ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the development of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-α and IL-6, which are known to promote the growth of myeloma cells in the bone marrow microenvironment. Dosage and Administration Guidelines Administration: Lynide 5 mg is an oral medication. Capsules must be swallowed whole with water. Do not open, crush, or chew the capsules. Consistency: It should be taken at approximately the same time each day, with or without food. Cycle-Based Therapy: In many maintenance protocols, it is taken daily on a 21-day or 28-day cycle. Always adhere to the specific regimen prescribed by your hematologist-oncologist. Dose Flexibility: The 5 mg strength allows clinicians to precisely adjust the dose to manage hematological toxicities or accommodate renal impairment. Safety Profile and Clinical Monitoring Due to its potent biological activity, Lynide 5 mg requires vigilant medical oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are mandatory to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Risk: Lenalidomide increases the risk of blood clots. Prophylactic anticoagulation (e.g., Aspirin) is frequently prescribed concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients, regardless of gender or age. Common Side Effects: These may include fatigue, diarrhea, muscle cramps, skin rashes, and nausea. Storage and Global Handling Instructions Temperature: Store at room temperature (20°C to 25°C). Original Packaging: Keep capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately with soap and water. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenome 5mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Hematological Oncology Lenome 5mg Capsule is a potent, oral antineoplastic and immunomodulatory medication containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Intas Pharmaceuticals Ltd., a global leader in high-quality oncology generics, Lenome belongs to the class of medications known as Immunomodulatory Imide Drugs (IMiDs). The 5mg strength is a vital dosage form used extensively for maintenance therapy, dose titration, and the management of chronic blood-related malignancies. Therapeutic Indications and Clinical Usage Lenome 5mg is integrated into international oncology protocols for the following conditions: Multiple Myeloma (MM): Used as a maintenance treatment in adult patients following an autologous stem cell transplant (ASCT) or in combination with dexamethasone for newly diagnosed or relapsed/refractory cases. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Used for patients whose disease has relapsed or progressed after at least two prior therapies, one of which included bortezomib. Follicular Lymphoma (FL): Administered in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lenome 5 mg Works Direct Cytotoxicity: It binds to the Cereblon (CRBN) protein, part of the E3 ubiquitin ligase complex. This leads to the selective degradation of essential transcription factors (Ikaros and Aiolos) that malignant B-cells and plasma cells rely on for survival. Anti-Angiogenesis: It inhibits the formation of new blood vessels (angiogenesis) by reducing levels of vascular endothelial growth factor (VEGF), essentially “starving“ the tumor of nutrients. Immune Modulation: It stimulates the proliferation and activation of T-cells and Natural Killer (NK) cells, boosting the immune system's ability to identify and destroy cancerous cells. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines like TNF-α and IL-6, which contribute to the survival and spread of cancer cells in the bone marrow microenvironment. Dosage and Administration Guidelines Administration: Lenome 5 mg should be taken orally, once daily, at approximately the same time each day. Method: Swallow the capsule whole with a full glass of water. Do not open, crush, or chew the capsules, as this can affect drug absorption and safety. Timing: It can be taken with or without food. Cycle-Based Therapy: In many protocols, it is taken on a 21-day or 28-day cycle. Always follow the specific dosing schedule prescribed by your oncologist. Safety Profile and Clinical Monitoring Due to its potent biological activity, Lenome 5 mg requires careful medical supervision: Hematological Monitoring: Regular Complete Blood Counts (CBC) are required to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Risk: Lenalidomide increases the risk of blood clots (DVT/PE). Prophylactic anticoagulation (e.g., Aspirin) is often prescribed concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. It is strictly contraindicated in pregnancy, and both male and female patients must adhere to rigorous pregnancy prevention programs. Common Side Effects: These may include fatigue, diarrhea, muscle cramps, skin rashes, and nausea. Storage and Global Handling Instructions Temperature: Store at room temperature (20°C to 25°C). Original Packaging: Keep capsules in the original bottle or blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication. Keep out of reach of children and pets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutib 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibitor for Targeted Oncology Care Sutib 12.5 mg Capsule is a high-potency oral therapeutic agent containing the active substance Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutib is a cornerstone in modern targeted cancer therapy. Manufactured by Cadila Pharmaceuticals (Zydus), it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Sutib 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often as a first-line therapy to improve progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Indicated for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy) in high-risk patients. Mechanism of Action: How Sutib 12.5mg Works Sutib works through a dual-mechanism approach to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutib 12.5 mg is an oral medication. Capsules should be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (37.5 mg or as adjusted) without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state levels. Safety Profile and Clinical Monitoring Treatment with Sutib 12.5 mg requires vigilant medical oversight for: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or hair depigmentation during the treatment cycle. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutib 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Malignancies Sutib 12.5 mg Capsule is a high-efficacy oral antineoplastic agent featuring the active pharmaceutical ingredient Sunitinib Malate. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutib is a cornerstone in modern precision oncology. Manufactured by Cadila Pharmaceuticals (Zydus), it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 28-capsule pack is the standard clinical format, meticulously dosed to facilitate the complex “on-off“ cycles required for effective tumor suppression. Therapeutic Indications and Global Clinical Usage Sutib 12.5mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sutib 12.5mg Works Sutib employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Pack Size: 28 Capsules per Bottle/Box. Administration: Sutib 12.5mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (37.5mg or adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with Sutib 12.5 mg requires consistent medical oversight to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutykine 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibitor for Targeted Oncology Care Sutykine 12.5 mg Capsule is a high-potency oral therapeutic agent containing the active substance Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutykine is a cornerstone in modern targeted cancer therapy. Manufactured by Zuventus Healthcare, it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Sutykine 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often as a first-line therapy. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Indicated for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy). Mechanism of Action: How Sutykine 12.5mg Works Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutykine helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutykine 12.5 mg is an oral medication. Capsules should be swallowed whole with water. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off. Continuous Regimen (pNET): Often prescribed as a continuous daily dose without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration (e.g., 25 mg, 37.5 mg, or 50 mg) based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day. Safety Profile and Clinical Monitoring Treatment with Sutykine 12.5 mg requires vigilant medical oversight for: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Pancreatic Health: Periodic blood tests to check liver enzymes and lipase levels are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or “hand-foot syndrome,“ which should be managed by the oncology team. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383